News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Dilon Diagnostics Release: Adding BSGI Molecular Breast Imaging to Breast Imaging Centers Significantly Improves Breast Cancer Detection

3/27/2012 10:51:42 AM

NEWPORT NEWS, Va., March 27, 2012 /PRNewswire/ -- Dilon Diagnostics -- According to the results from a new multi-center patient registry, presented at the National Consortium of Breast Centers Annual Meeting on March 11th, 2012, Breast-Specific Gamma Imaging (BSGI) also known as Molecular Breast Imaging (MBI) improves breast cancer detection when added to mammography and ultrasound in the breast clinic.

In this study, BSGI/MBI detected cancers in nearly 13% of patients with negative or indeterminate mammograms and an unresolved diagnostic concern such as subtle changes in the mammogram, breast pain, a new breast lump, nipple discharge, etc. Another 4% of these patients had a high-risk lesion detected by BSGI/MBI. BSGI performed significantly better than ultrasound, detecting 92% of cancers compared to just 60% by ultrasound.

According to co-author Dr. Jean Weigert of Mandell and Blau MDs PC, New Britain, CT, "The primary advantage of ultrasound is that it does not use radiation, however, a negative ultrasound can still miss cancers. Our results demonstrate that in cases where mammography and ultrasound are negative or indeterminate, BSGI can still detect some cancers. The BSGI study does involve low doses of radiation, but the benefit of early cancer detection dwarfs the health risk from the radiation dose. In fact, there has never been a reported health impact from such low radiation doses and the benefit is evident in our data. Even according to the most conservative risk-models, the benefit outweighs the risk 680 to 1."


As a follow-up to mammography, BSGI/MBI utilizes the Dilon 6800® Gamma Camera to help physicians more clearly differentiate benign from malignant tissue. To perform BSGI/MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the BSGI/MBI image.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI/MBI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI/MBI to their patients, such as Cornell University Medical Center, New York and The George Washington University Medical Center, Washington, D.C. For more information on Dilon Technologies please visit

Media contact: Pjerin Luli
P: 757-269-4910

SOURCE Dilon Diagnostics

Read at

comments powered by Disqus